Renaissance Technologies LLC Buys Shares of 228,000 Liquidia Co. (NASDAQ:LQDA)

Renaissance Technologies LLC purchased a new position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 228,000 shares of the company's stock, valued at approximately $2,681,000. Renaissance Technologies LLC owned 0.27% of Liquidia as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LQDA. Vanguard Group Inc. boosted its stake in shares of Liquidia by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock valued at $41,834,000 after buying an additional 115,367 shares during the period. LM Advisors LLC purchased a new position in shares of Liquidia in the 4th quarter valued at approximately $25,948,000. Geode Capital Management LLC grew its position in Liquidia by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock valued at $15,753,000 after buying an additional 101,597 shares during the last quarter. Invesco Ltd. raised its holdings in Liquidia by 2,675.0% during the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after purchasing an additional 674,940 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Liquidia by 9.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock worth $5,040,000 after buying an additional 38,313 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Price Performance

LQDA traded up $0.46 during trading hours on Wednesday, reaching $13.97. 1,673,438 shares of the stock traded hands, compared to its average volume of 974,946. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -8.57 and a beta of 0.23. The firm's fifty day simple moving average is $14.29 and its two-hundred day simple moving average is $12.94.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, research analysts predict that Liquidia Co. will post -1.51 earnings per share for the current year.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the completion of the transaction, the insider now owns 263,152 shares in the company, valued at approximately $3,597,287.84. This trade represents a 0.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason Adair sold 1,856 shares of the company's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now directly owns 184,304 shares in the company, valued at approximately $2,501,005.28. This represents a 1.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,138 shares of company stock worth $450,233 in the last ninety days. 30.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages recently commented on LQDA. Scotiabank reiterated an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC reiterated a "buy" rating and issued a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).